When will ImmunityBio report results and how does that affect IBRX stock?

ImmunityBio will review FY2025 results and provide a business update on Mar 3, 2026. The report is a catalyst for IBRX stock because clinical readouts and cash guidance can rapidly change investor sentiment and intraday price action.

What are the main risks investors should watch for in IBRX stock?

Key risks for IBRX stock are negative clinical outcomes, faster cash burn than guided, and valuation re-rating. Watch R&D spending, cash runway, and any mid-trial safety signals that could alter development timelines.

How does Meyka AI view the upside or downside for IBRX stock?

Meyka AI's forecast model projects **$2.19** for the next year for IBRX stock, implying **-77.06%** versus the current price. Models are projections and not guarantees; use them with clinical and cash metrics.

Is ImmunityBio covered positively by analysts and does that impact IBRX stock?

Analyst coverage skews positive with **9** Buy ratings and no Holds or Sells. That cluster of Buy calls supports bullish sentiment for IBRX stock, but high valuation and binary clinical risk keep trading volatile.

US Stocks

IBRX (ImmunityBio) pre-market: Q4 2025 results Mar 3, 2026 could move stock

ByDanny Kontos March 2, 2026March 2, 2026

IBRX stock trades at $9.55 pre-market as ImmunityBio, Inc. (NASDAQ: IBRX) prepares to release fiscal Q4 and full-year 2025 results on Mar 3, 2026. Investors will focus on clinical progress for ANKTIVA and other pipeline programs, plus cash burn and guidance. Volume is elevated at 37,880,600.00 versus an average of 34,049,421.00, signaling heavy interest. This earnings spotlight reviews what the report must show to justify the recent run, and which metrics could drive intraday moves in the United States market